Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice
- 1.9k Downloads
Obesity-induced liver disease (nonalcoholic fatty liver disease, NAFLD) is now the commonest cause of chronic liver disease in affluent nations. There are presently no proven treatments for NAFLD or its more severe stage, nonalcoholic steatohepatitis (NASH). Bofutsushosan (BTS), a Japanese herbal (Kampo) medicine, long used as an anti-obesity medicine in Japan and other Asian countries, has been shown to reduce body weight and improve insulin resistance (IR) and hepatic steatosis. The precise mechanism of action of BTS, however, remains unclear. To evaluate the ability of BTS to prevent the development of NASH, and determine the mediators and pathways involved.
C57BL/6 mice were injected intra-peritoneally with gold-thioglucose and fed a high-fat diet (HF) or HF diet admixed with either 2 or 5 % BTS for 12 weeks. The effectiveness of BTS in attenuating features of NASH and the mechanisms through which BTS attenuated NASH were then assayed through an assessment of the anthropometric, radiological, biochemical and histological parameters.
BTS attenuated the progression of NASH through induction of adiponectin and its receptors along with an induction of PPAR-α and PPAR-γ, decreased expression of SREBP-1c, increased hepatic fatty acid oxidation and increased hepatic export of triglycerides. BTS moreover, reduced IR through phosphorylation of the protein kinase, Akt.
BTS through induction of adiponectin signaling and Akt attenuated development of NASH. Identification of the active entity in BTS should allow development of novel treatments for NASH.
KeywordsNAFLD Adiponectin Bofutsushosan Kampo medicine
Nonalcoholic fatty liver disease
Impaired glucose tolerance
Glucose tolerance test
Insulin tolerance test
Quantitative insulin sensitivity check index
Medium-chain acyl-CoA dehydrogenase
Tissue inhibitor of metalloproteinases
Transforming growth factor
Microsomal triglyceride transfer protein
AMP-activated protein kinase
Obesity-induced liver disease (nonalcoholic fatty liver disease, NAFLD), is now the commonest cause of chronic liver disease in affluent nations. The disease comprises obesity and insulin resistance (IR), with a consequent histopathological spectrum of hepatosteatosis, steatohepatitis (nonalcoholic steatohepatitis, NASH), cirrhosis and possible hepatocellular cancer [1, 2, 3]. There are presently no proven treatments for NAFLD or its more severe stage NASH. Bofutsushosan (BTS), a Japanese herbal (Kampo) medicine, long used as an anti-obesity medicine in Japan and other Asian countries  has recently been shown in obese Japanese women, to reduce body weight and improve IR . In addition, BTS in experimental animals prevented adipogenesis , reduced weight, suppressed visceral and subcutaneous fat accumulation and in parallel decreased plasma glucose, triglycerides (TG), insulin, tumor necrosis factor-alpha , and hepatic steatosis induced by high-fat diet feeding [7, 8]. The mechanism of action of BTS however, is not known. Our aim here was to evaluate the ability of BTS to prevent the development of NASH in a recently described murine model involving administration of gold-thioglucose (GTG) and high-fat feeding to induce NASH , and to determine the mediators and pathways involved.
Materials and methods
All procedures conformed to our institutions’ guidelines for the care and use of animals in Kochi Medical School. Four-week-old male C57BL/6 mice were purchased from CLEA Japan Inc. All animals were housed for 12 weeks on a 12 h light/12 h dark cycle, with food and water freely available. Mice were fed high-fat-diet (HF, 640 kcal/100 g, F2HFD2, Oriental Yeast, Tokyo, Japan) or HF admixed with 2 or 5 % BTS (TJ-62, Tsumura & Co., Tokyo, Japan). All groups were fed standard chow (SC) for the first week and then continued on their respective group diets for remainder of the protocol.
Three experimental groups were studied: (1) intra-peritoneal administered GTG (2 mg/g of body weight, Sigma-Aldrich, St. Louis, MO, USA) and then SC for 1 week followed by HF diet for 11 weeks (GTG + HF) ; (2 and 3) intra-peritoneal GTG, SC for 1 week followed by HF diet admixed with either 2 %BTS or 5 % BTS for further 11 weeks (2 %BTS or 5 % BTS). At the end of the treatment period, all animals were fasted overnight, anesthetized with pentobarbital sodium intraperitoneally (25–50 mg/kg of body weight, Nembutal; Abbott Laboratories, Abbott Park, IL, USA). Blood and liver samples were harvested. Livers were fixed in 10 % formalin, or snap frozen in liquid nitrogen and stored at −80 °C, for later analyses.
CT scan analysis for body fat composition
The extent of adiposity in each experimental group was assayed by CT scanning (La Theta, ALOKA, Tokyo, Japan) under isoflurane (2 % v/v) anesthesia as described previously . Animal were scanned at 2-mm intervals from the diaphragm to the pelvis, and visceral fat and subcutaneous fat volumes quantified with La Theta software (version 1.00) [9, 10, 11].
Five-micrometer sections of formalin-fixed/paraffin-embedded livers were processed for haematoxylin and eosin (H&E). Oil Red-O staining of intracellular neutral lipids was performed according to the manufacturer’s instructions (Sigma-Aldrich, St. Louis, MO, USA). For estimation of extent of hepatic steatosis, the areas of digital photomicrographs were quantified with a computerized image analysis system (macintosh MacSCOPE version 2.591) as described previously [9, 12]. Degree of oxidative stress was determined by staining and quantification with anti-8-hydroxy-2′-deoxyguanosine (8-OHdG) and anti-4-hydroxy-2-nonenal (4-HNE) as previously described [9, 12, 13].
Glucose tolerance test (GTT), insulin tolerance test (ITT) and QUICKI
At 12 weeks, a glucose tolerance test (GTT) (n = 6) and an insulin tolerance test (ITT) (n = 6) were performed. For GTT, mice were fasted for 18 h, and then intra-peritoneally loaded with 20 % glucose at a dose of 1.0 g/kg body weight. For ITT, mice were fasted for 6 h, and then intra-peritoneally challenged with human insulin at 1.0 U/kg body weight [14, 15]. With both GTT and ITT blood samples from the orbital sinus were taken at times 0, 30, 45, 60 and 120 min and plasma glucose concentrations measured using an automatic blood glucose meter (Glutest; Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan). Plasma insulin level was measured by Ultrasensitive Mouse Insulin ELISA kit (Mercodia AB, Uppsala, Sweden) according to the manufacture’s protocol. The quantitative insulin sensitivity check index (QUICKI), as a measure of IR, was calculated from the fasting insulin and glucose levels.
Measurement of plasma adiponectin
Plasma adiponectin levels were measured by Mouse Adiponectin/Acrp30 (R&D Systems, Minneapolis, MN, USA) according to the manufacture’s instructions.
Asparate aminotransferase (AST), alanine aminotransferase (ALT) and TG were measured by an autoanalyzer (BM6010; JEOL Ltd., Tokyo, Japan).
Real-time RT-PCR for quantitative assessment of mRNA expression
Total RNA was extracted using trizol reagent (Life Technologies, Grand Island, NY, USA) according to the manufacture’s protocol. RNA extracts were reverse-transcribed with random hexamers and avian myeloblastosis virus reverse transcriptase using a commercial kit (Takara, Kyoto, Japan). Real time RT-PCR were performed for quantitative assessment of mRNA expression on an ABI Prism 7000 Sequence Detection system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s protocol. Probes and primers for TNF-α, PPAR-α, PPAR-γ, MTP, DGAT2, Cyp2E1, adiponectin receptor 1/receptor 2 (AdipoR1/R2) were all purchased from Applied Biosystems. Relative expression of target gene mRNA was normalized to the amount of GAPDH mRNA.
Western blot analysis
For in vivo analysis of phosphorylated Akt and total Akt, mice were fasted for 18 h, injected intra-peritoneally with human insulin (10 U/kg) or control, and sacrificed 4 min later. Livers were snap frozen in liquid nitrogen. Liver total protein was analyzed by western blot with a polyclonal antibody to phosphorylated Akt/Akt and phosphorylated AMPK/AMPK (Cell Signaling Technology, Inc., Danvers, MA, USA) as described . For analysis of SREBP-1c, mice were fasted for 18 h, sacrificed, and livers dissected and homogenized to prepare cell nuclear extracts which were then analyzed by western blotting with anti-SREBP-1c antibody (Santa Cruz Biotechnology, Inc., California, CA, USA) as described . For analysis of 4-HNE, liver total protein was analyzed by western blot with a monoclonal anti-4-HNE antibody (Japan Institute for the Control of Aging, Shizuoka, Japan).
Data are shown as mean ± SD. A univariate analysis was conducted with the Mann–Whitney U test to determine significance between groups. Qualitative data were compared using Fisher’s exact test. Statistical significance was accepted at p < 0.05. All analyses were performed using Stat View software (SAS Institute, Cary, NC, USA).
BTS treatment reduces GTG + HF induced obesity and steatohepatitis
Physiological and biochemical analyses in mice treated with BTS
SC (n = 6)
GTG + HF (n = 6)
2 %BTS (n = 6)
5 %BTS (n = 6)
86 ± 11
310 ± 114
271 ± 27
170 ± 46*
31 ± 9
514 ± 170
433 ± 37
299 ± 133*
36 ± 7
37 ± 13
52 ± 11*
49 ± 8
BTS inhibition of hepatic lipid metabolism occurs through induction of adiponectin signaling
Attenuation of hepatic steatosis with BTS treatment involves activation of fatty acid oxidation
Additionally, the expression of PPAR-α and its target genes, MCAD, involved in mitochondrial β-oxidation and CYP2E-1 involved in microsomal ω-oxidation [21, 22] were increased by treatment with BTS (Fig. 4e–g).
BTS promotes hepatic lipid export
We next determined if enhanced secretion of TG from the liver could contribute to the attenuation of hepatic steatosis by BTS treatment. The expression of microsomal triglyceride transfer protein (MTP) known to play a central role in lipoprotein assembly  was increased with BTS treatment (Fig. 4h). Interestingly, expression of DGAT2 reported to be involved in the conversion of free fatty acids into TG in the liver  was also increased in the BTS treated groups (Fig. 4i).
BTS reduces glucose intolerance and insulin resistance through induction of Akt
The public health importance of NAFLD [1, 2] and the unavailability of proven and effective therapies drive the search for a greater understanding of its pathophysiology and novel therapeutic pathways. In this study, we have clarified the mechanisms through which BTS attenuates NASH based on a novel animal model of NASH . BTS attenuated the GTG + HF induced increases in body and liver weight, serum transaminases, hepatic steatosis, degree of oxidative stress and TNF-α expression (Figs. 1, 2, 3; Table 1) without reducing intake volume of diets (data not shown). However, in contrast to previous reports , we did not demonstrate statistically remarkable reduction by BTS, in GTG + HF mice, of induced increases in visceral or subcutaneous fat (Fig. 1b), perhaps because the volume of these fats in our mice were much larger than previously reported . Additionally, the reduction of body weight might mainly be through the reduction of fat accumulation in muscles, since it has been reported that the degree of hepatosteatosis is well correlated with the degree of fat accumulation in muscles .
To examine the mechanisms though which BTS attenuated hepatic steatosis, we firstly evaluated the effect of BTS on adiponectin, thought to be a central adipokine in the pathogenesis for NASH [18, 19]. The expression of AdipoR1 and AdipoR2 in the livers was increased in a dose dependent manner by BTS (Fig. 4a), indicating that BTS could have PPAR-α agonist like effect, since PPAR-α agonists are known to increase expression of AdipoR1 and AdipoR2 . Interestingly, plasma adiponectin levels were also remarkably induced by BTS treatment (Fig. 4a) even though neither visceral nor subcutaneous fat were decreased. These data indicated that BTS through putative PPAR-γ effects may also function to increase serum adiponectin, since PPAR-γ agonists have been shown to positively regulate serum adiponectin independently of adipose tissue volume regulation [28, 29].
To now study the mechanisms of inhibition of liver lipid metabolism by BTS in the presence of the activated adiponectin signaling pathway, AdipoR1 signaling pathways and their target genes were examined. It is known that activated AdipoR1 signaling decreases expression of SREBP-1c , a key regulator of hepatic fatty acid synthesis [31, 32], through AMPK activation . Here, we showed increased phosphorylation of AMPK by BTS in parallel with activated AdipoR1 signaling (Fig. 4c). Additionally, the phosphorylation of AMPK could also have been induced by activated PPAR-γ, in BTS treated mice, since as above BTS could also have PPAR-γ agonist like actions. Moreover, in the livers of mice treated with BTS, there was a reduced expression of SREBP-1c (Fig. 4b) in parallel with activated adiponectin signaling and phosphorylation of AMPK.
TNF-α expression is also known to regulate expression of SREBP-1c through activation of AMPK [31, 34]. Therefore, the suppression of TNF-α expression by BTS, as observed here, could also have contributed to the decreased SREBP-1c expression. Taken together, therefore, the data here suggest that activation of AdipoR1 signaling and consequent suppression of SREBP-1c may be central mechanisms through which BTS attenuates hepatic steatosis.
BTS may also have enhanced hepatic fatty acid oxidation via AdipoR2 signaling, known to increase the expression of PPAR-α  and its fatty acid oxidation related target genes. Here, the expression of PPAR-α (Fig. 4e) and its target gene MCAD (Fig. 4f) and CYP2E1 (Fig. 4g), were increased by treatment with BTS. Therefore, activated fatty acids oxidation could also contribute to the attenuation of hepatic steatosis by BTS. Activation of fatty acid oxidation would be expected to increase production of reactive oxygen species (ROS) in the liver [35, 36]. BTS treatment here reduced ROS levels, probably contributing to the improved hepatic inflammation observed with BTS.
Additionally, MTP expression was confirmed here to be increased by treatment with BTS, possibly contributing to attenuation of steatosis by increasing hepatic export of TG (Fig. 4h). Interestingly, expression of DGAT2 was also increased by BTS treatment (Fig. 4i). Reduced hepatic accumulation of TG in BTS-treated livers may therefore have been due to increased MTP expression and increased expression of DGAT2 to reduce the content of FFA. Furthermore, increased expression of DGAT2 might also have contributed to the reduction of ROS production by reducing hepatic FFA availability.
We next also investigated the effect of BTS on IR. GTG + HF induced elevation of fasting plasma glucose and plasma insulin were markedly reduced by BTS treatment, whilst QUICKI was markedly increased by BTS (Fig. 5a). In addition, ITT also was attenuated by BTS treatment. Furthermore, GTT showed that BTS remarkably attenuated severe glucose intolerance induced by GTG + HF (Fig. 5b). Phosphorylation of hepatic Akt after administration of insulin was reduced by treatment of BTS (Fig. 5c). The mechanisms through which BTS improves insulin sensitivity may involve Akt phosphorylation triggered through as yet uncertain mechanisms, but possibly involving induction of adiponectin signaling by BTS, since adiponectin is known to be involved in the suppression of hepatic gluconeogenesis and insulin secretion by activating AMPK .
In conclusion, therefore, BTS—a Japanese anti-obesity herbal (Kampo) medicine—is an effective preventive agent against the development of NASH. The challenge is now to identify the active components of BTS to allow its refinement and the rational design of more potent analogues.
Grants-in-Aid for Scientific Research (C) 2009 Grant # 20590785, The Ministry of Education, Science, Sports and Culture, Japan (Masafumi Ono). Wellcome Trust, UK (Jude A. Oben).
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Yamakawa J, Ishigaki Y, Takano F, Takahashi T, Yoshida J, Moriya J, et al. The Kampo medicines Orengedokuto, Bofutsushosan and Boiogito have different activities to regulate gene expressions in differentiated rat white adipocytes: comprehensive analysis of genetic profiles. Biol Pharm Bull. 2008;31:2083–9.PubMedCrossRefGoogle Scholar
- 9.Ogasawara M, Hirose A, Ono M, Aritake K, Nozaki Y, Takahashi M, et al. A novel and comprehensive mouse model of human non-alcoholic steatohepatitis with the full range of dysmetabolic and histological abnormalities induced by gold thioglucose and a high-fat diet. Liver Int. 2011;31:542–51.PubMedCrossRefGoogle Scholar
- 11.Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, et al. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes. 2005;54:1000–8.PubMedCrossRefGoogle Scholar
- 13.Albrecht C, Knaapen AM, Becker A, Höhr D, Haberzettl P, van Schooten FJ, et al. The crucial role of particle surface reactivity in respirable quartz-induced reactive oxygen/nitrogen species formation and APE/Ref-1 induction in rat lung. Respir Res. 2005;6:129.PubMedCentralPubMedCrossRefGoogle Scholar
- 28.Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005;54:3358–70.PubMedCrossRefGoogle Scholar
- 34.Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood). 2007;232:614–21.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.